MedTrace Logo

Comprehensive Analysis of Relapse in Multiple Sclerosis

NCT01906684 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-08-01

No results posted yet for this study

Summary

This study will determine changes in: 1) the immune activity, characterized as the "immunorepertoire;" 2) 7 Tesla MRI brain images; 3) clinical outcomes; and 4) patient reported quality of life outcomes in subjects with relapsing-remitting multiple sclerosis who are treated with Acthar Gel.

Conditions

Interventions

DRUG

Acthar Gel

Patients who present with MS relapse within 72 hours of onset will be recruited for study. Upon consent they will be administered Achtar Gel for 5-14 days as clinically appropriate.

Sponsors & Collaborators

  • Mallinckrodt

    collaborator INDUSTRY

  • Auburn University MRI Research Center

    collaborator UNKNOWN

  • iReportoire Inc

    collaborator UNKNOWN

  • Tanner Foundation for Multiple Sclerosis

    lead OTHER

Principal Investigators

  • Emily S Riser, MD · Tanner Center for MS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01906684 on ClinicalTrials.gov